Articles related to BIOLOGIC TREATMENTS

ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.

Accumulating evidence suggests that initiating effective therapy earlier in Crohn’s disease may reduce bowel damage progression, hospitalizations, and surgery. Long-term follow-up from recent studies has strengthened interest in a therapeutic window during which disease modification may be achievable.

A first joint EULAR/PReS guideline unifies systemic juvenile idiopathic arthritis and adult-onset Still’s disease under a single name, Still’s disease, and recommends early IL-1 or IL-6 inhibitor therapy over prolonged glucocorticoid use.

The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.

A pediatric gastroenterology expert outlines when extrapolation of adult IBD therapies to children is reasonable, where it falls short, and how shared decision-making should be structured.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.